Market Overview

UPDATE: Credit Suisse Initiates Cubist Pharmaceuticals at Neutral; Expecting Positive Readouts

Related CBST
Stocks Hitting 52-Week Highs
State Of The Union Lights Up Biotech

Credit Suisse initiated coverage on Cubist Pharmaceuticals (NASDAQ: CBST) with a Neutral rating and a $52.00 price target.

Credit Suisse analyst Jason Kantor commented, "We expect that positive CXA-201 data in H2:13 will increase confidence in the long-term sustainability of CBST's antibiotic franchise and lay the ground work for global expansion. Data from a recently optioned Phase II asset will also read out in the same timeframe. Near-term expenses and cash outlays may limit near-term upside."

Cubist Pharmaceuticals closed at $47.47 on Thursday.

Latest Ratings for CBST

Dec 2014UBSDowngradesBuyNeutral
Dec 2014RBC CapitalDowngradesOutperformSector Perform
Dec 2014JefferiesDowngradesBuyHold

View More Analyst Ratings for CBST
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Analyst Ratings


Related Articles (CBST)

View Comments and Join the Discussion!

Partner Center